Yahoo Web Search

Search results

    • Novo Nordisk: Growth Is Still A Better Choice

      Novo Nordisk: Growth Is Still A Better Choice

      GuruFocus.com via Yahoo Finance· 15 hours ago

      Subsequently...as well as the switching of patients from Victoza (liraglutide) since the launch of its generic versions is expected in mid-2024. Source:...

    • Takeda Pharmaceutical: A Long-Term Cash Cow

      Takeda Pharmaceutical: A Long-Term Cash Cow

      GuruFocus.com via Yahoo Finance· 7 days ago

      Moreover, thanks to the steps taken by the company's CEO to optimize administrative and general expenses, label expansions...the treatment of Hodgkin's...